Moderna, Inc. $MRNA Shares Sold by Profund Advisors LLC

Profund Advisors LLC lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 39.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,994 shares of the company’s stock after selling 13,148 shares during the quarter. Profund Advisors LLC’s holdings in Moderna were worth $3,850,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Western Pacific Wealth Management LP bought a new position in shares of Moderna in the 3rd quarter worth $29,000. Ramsey Quantitative Systems bought a new stake in Moderna in the third quarter valued at approximately $40,000. Fortitude Family Office LLC increased its position in shares of Moderna by 53.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock valued at $43,000 after acquiring an additional 77 shares during the period. MADDEN SECURITIES Corp purchased a new position in Moderna during the 3rd quarter valued at about $55,000. Finally, Allied Private Wealth LLC bought a new position in shares of Moderna during the second quarter valued at approximately $30,000. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $221.72 on Friday. The stock has a 50 day moving average price of $182.49 and a 200-day moving average price of $86.52. The stock has a market cap of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a one year low of $22.28 and a one year high of $254.48.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.13) EPS. Equities analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MRNA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Barclays upped their price objective on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Jefferies Financial Group reissued a “hold” rating and issued a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Finally, Bank of America raised their target price on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $107.10.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.